ERYTECH reports financial highlights for Q3 2015 admERY November 3, 2015 Newsroom ERYTECH reports cash balance and revenues for the third quarter of 2015. You Might Also Like ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia June 24, 2018 ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014 ERYTECH to raise approximately € 25.4 million in a private placement of ordinary shares to European and U.S. institutional investors December 3, 2015
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia June 24, 2018
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014
ERYTECH to raise approximately € 25.4 million in a private placement of ordinary shares to European and U.S. institutional investors December 3, 2015
